Dementia in Down syndrome: unique insights for Alzheimer disease research

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657

Calcium's Role in Mechanotransduction during Muscle Development

Damm, T. B., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,552

Mild Cognitive Impairment: Clinical Characterization and Outcome

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980

The amyloid hypothesis of Alzheimer's disease at 25 years

Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164

Sleep Drives Metabolite Clearance from the Adult Brain

Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404

Inflammation and Alzheimer’s disease

Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092

Oxidative stress and the amyloid beta peptide in Alzheimer’s disease

Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185

Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome

Lee, S. E., Duran-Martinez, M., Khantsis, S., Bianchi, D. W., & Guedj, F. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.001 · Cited by 25

Focusing on cellular biomarkers: The endo-lysosomal pathway in Down syndrome

Botté, A., & Potier, M. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.002 · Cited by 22

Oxidative Stress in Down and Williams-Beuren Syndromes: An Overview

Ferrari, M., & Stagi, S. (2021) · Molecules · doi:10.3390/molecules26113139 · Cited by 27

Emergence of distinct and heterogeneous strains of amyloid beta with advanced Alzheimer’s disease pathology in Down syndrome

Maxwell, A. M., Yuan, P., Rivera, B. M., Schaaf, W., Mladinov, M., Prasher, V. P., Robinson, A. C., DeGrado, W. F., & Condello, C. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01298-0 · Cited by 23

AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome

Hartley, S. L., Handen, B. L., Tudorascu, D., Lee, L., Cohen, A. D., Schworer, E. K., Peven, J. C., Zammit, M. D., Klunk, W. E., Laymon, C. M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13446 · Cited by 23

Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome

Rafii, M. S., Zaman, S. H., & Handen, B. L. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.35 · Cited by 23

Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS) study

Petersen, M. E., Zhang, F., Schupf, N., Krinsky‐McHale, S. J., Hall, J. R., Mapstone, M. E., Cheema, A. K., Silverman, W. P., Lott, I. T., Rafii, M. S., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12039 · Cited by 22

Transcriptional and Post-Transcriptional Regulations of Amyloid-β Precursor Protein (APP) mRNA

Sato, K., Takayama, K., Hashimoto, M., & Inoue, S. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.721579 · Cited by 24

Development of Down Syndrome Research Over the Last Decades–What Healthcare and Education Professionals Need to Know

Windsperger, K., & Hoehl, S. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.749046 · Cited by 23

Neurogenesis and neuronal differentiation in the postnatal frontal cortex in Down syndrome

Utagawa, E. C., Moreno, D. G., Schafernak, K. T., Arva, N. C., Malek‐Ahmadi, M. H., Mufson, E. J., & Perez, S. E. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01385-w · Cited by 24

Cryo-EM structures reveal tau filaments from Down syndrome adopt Alzheimer’s disease fold

Ghosh, U., Tse, E., Yang, H., Shi, M., Caro, C. D., Wang, F., Merz, G. E., Prusiner, S. B., Southworth, D. R., & Condello, C. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01806-y · Cited by 27

Common genetic signatures of Alzheimer’s disease in Down Syndrome

Sharma, A., Chunduri, A., Gopu, A., Shatrowsky, C., Crusio, W. E., & Delprato, A. (2020) · F1000Research · doi:10.12688/f1000research.27096.1 · Cited by 22

Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer's disease and the Dp16 mouse Down syndrome model: Impact of APP gene dose

Chen, X., Zuo, X., Becker, A., Head, E., & Mobley, W. C. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12835 · Cited by 23

Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome

Chen, X., Xing, Z., Chen, Q.-D., Salvi, R., Zhang, X., Tycko, B., Mobley, W. C., & Yu, Y. E. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.700280 · Cited by 26

Cooperation between neurovascular dysfunction and Aβ in Alzheimer’s disease

Wang, N., Yang, X., Zhao, Z., Liu, D., Wang, X., Tang, H., Zhong, C., Chen, X., Chen, W. K., & Meng, Q. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1227493 · Cited by 22

Exploring the role of sex differences in Alzheimer's disease pathogenesis in Down syndrome

Andrews, E. J., Martini, A. C., & Head, E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.954999 · Cited by 21

Characterization of white matter hyperintensities in Down syndrome

Morcillo-Nieto, A. O., Zsadanyi, S. E., Arriola‐Infante, J. E., Carmona‐Iragui, M., Montal, V., Pegueroles, J., Aranha, M. R., Vaqué‐Alcázar, L., Padilla, C., Benejam, B., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14146 · Cited by 22

Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease

Kac, P. R., Alcolea, D. A., Montoliu‐Gaya, L., Fernández, S., Lantero‐Rodriguez, J., Maure‐Blesa, L., González‐Ortiz, F., Benejam, B., Turton, M., Barroeta, I., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70172 · Cited by 22

EMBER multidimensional spectral microscopy enables quantitative determination of disease- and cell-specific amyloid strains

Yang, H., Yuan, P., Wu, Y., Shi, M., Caro, C. D., Tengeiji, A., Yamanoi, S., Inoue, M., DeGrado, W. F., & Condello, C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300769120 · Cited by 19

Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring

Petersen, M. E., Aguilar, L. F., Head, E., Montoliu‐Gaya, L., Strydom, A., Pape, S. E., Fortea, J., Ashton, N. J., Udeh‐Momoh, C. T., O’Bryant, S. E., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14364 · Cited by 20

Down syndrome biobank consortium: a perspective

Aldecoa, I., Barroeta, I., Carroll, S. L., Fortea, J., Gilmore, A., Ginsberg, S. D., Guzman, S. J., Hamlett, E. D., Head, E., Perez, S. E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13692 · Cited by 19

Blood circulating miR-28-5p and let-7d-5p associate with premature ageing in Down syndrome

Morsiani, C., Bacalini, M. G., Collura, S., Moreno‐Villanueva, M., Breusing, N., Bürkle, A., Grune, T., Franceschi, C., de Eguileor, M., & Capri, M. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111691 · Cited by 18

Shaping down syndrome brain cognitive and molecular changes due to aging using adult animals from the Ts66Yah murine model

Lanzillotta, C., Rataj-Baniowska, M., Prestia, F., Sette, C., Nalesso, V., Marzia Perluigi, A., Barone, E., Duchon, A., Tramutola, A., Hérault, Y., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106523 · Cited by 21

Suppression of eEF2 phosphorylation alleviates synaptic failure and cognitive deficits in mouse models of Down syndrome

Wang, X., Yang, Q., Zhou, X., Keene, C. D., Ryazanov, A. G., & Ma, T. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13916 · Cited by 17

Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study

Janelidze, S., Collij, L. E., Mattsson, N., Antill, A., Laymon, C. M., Lott, I. T., Rosas, H. D., Minhas, D. S., Luo, W., Zaman, S. H., et al. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00158-9 · Cited by 18

Detecting Alzheimer’s Dementia Degree

Wu, E. Q., Peng, X.-Y., Chen, S.-D., Zhao, X.-Y., & Tang, Z. (2022) · IEEE Transactions on Cognitive and Developmental Systems · doi:10.1109/tcds.2020.3015131 · Cited by 17

Identifying dementia in Down syndrome with the Severe Impairment Battery, Brief Praxis Test and Dementia Scale for People with Learning Disabilities

Wallace, E. R., Harp, J. P., Pelt, K. L. V., Koehl, L., Caban‐Holt, A., Anderson-Mooney, A. J., Jicha, G. A., Lightner, D. D., Robertson, W. C., Head, E., et al. (2021) · Journal of Intellectual Disability Research · doi:10.1111/jir.12901 · Cited by 17

Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium

Sexton, C. E., Solis, M., Aharon‐Peretz, J., Alexopoulos, P., Apostolova, L. G., Bayen, É., Birkenhager, B., Cappa, S. F., Constantinidou, F., Fortea, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12588 · Cited by 20

Rise of the human-mouse chimeric brain models

Jiang, P., & Alam, M. M. (2022) · Cell Regeneration · doi:10.1186/s13619-022-00135-6 · Cited by 16

Exploring facile synthesis and cholinesterase inhibiting potential of heteroaryl substituted imidazole derivatives for the treatment of Alzheimer’s disease

Chaudhry, F., Munir, R., Ashraf, M., Mehr-un-Nisa, Huma, R., Malik, N., Hussain, S., Munawar, M. A., & Khan, M. A. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2022.104384 · Cited by 17

Research attitudes in families of individuals with Down syndrome: importance for clinical trials

Lott, I. T., Kirby, K. A., Doran, E. W., & Grill, J. D. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01120-6 · Cited by 17

Cognitive and functional performance and plasma biomarkers of early Alzheimer's disease in Down syndrome

Schworer, E. K., Handen, B. L., Petersen, M. E., O’Bryant, S. E., Peven, J. C., Tudorascu, D., Lee, L., Krinsky‐McHale, S. J., Hom, C. L., Clare, I. C. H., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12582 · Cited by 17

Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

Gkanatsiou, E., Sahlin, C., Portelius, E., Johannesson, M., Söderberg, L., Fälting, J. M., Basun, H., Möller, C., Odergren, T., Zetterberg, H., et al. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135894 · Cited by 18

The role of interferon signaling in neurodegeneration and neuropsychiatric disorders

Sirkis, D. W., Oddi, A. P., Jonson, C., Bonham, L. W., Hoang, P. T., & Yokoyama, J. S. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1480438 · Cited by 16

Screening of dementia indicating signs in adults with intellectual disabilities

Arvio, M., & Bjelogrlic‐Laakso, N. (2021) · Journal of Applied Research in Intellectual Disabilities · doi:10.1111/jar.12888 · Cited by 16

A scoping review of post-diagnostic dementia supports for people with intellectual disability

Dennehy, H., Allen, A. P., McGlinchey, E., Buttery, N., García-Domínguez, L., Chansler, R., Corr, C., Dunne, P., Kennelly, S., Daly, L., et al. (2022) · Aging & Mental Health · doi:10.1080/13607863.2022.2130171 · Cited by 16

Timing of Alzheimer’s Disease by Intellectual Disability Level in Down Syndrome

Hartley, S. L., Fleming, V., Schworer, E. K., Peven, J. C., Handen, B. L., Krinsky‐McHale, S. J., Hom, C. L., Lee, L., Tudorascu, D., Laymon, C. M., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230200 · Cited by 18

Locked in a vicious cycle: the connection between genomic instability and a loss of protein homeostasis

Huiting, W., & Bergink, S. (2020) · Genome Instability & Disease · doi:10.1007/s42764-020-00027-6 · Cited by 17

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discovery

Videla, L., Benejam, B., Barroeta, I., Fernández, S., Altuna, M., Arranz, J., Rodríguez‐Baz, Í., Arriola‐Infante, J. E., Maure‐Blesa, L., Soriano, L. D. H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70259 · Cited by 17

Genetics and genomics of Down syndrome

Strippoli, P., Pelleri, M. C., Piovesan, A., Caracausi, M., Antonaros, F., & Vitale, L. (2019) · International review of research in developmental disabilities · doi:10.1016/bs.irrdd.2019.06.001 · Cited by 17

Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders

Bartesaghi, R., Vicari, S., & Mobley, W. C. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-041521-103641 · Cited by 18

REST Targets JAK–STAT and HIF-1 Signaling Pathways in Human Down Syndrome Brain and Neural Cells

Huang, T., Fakurazi, S., Cheah, P.-S., & Ling, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129980 · Cited by 15

Integration of ATAC-seq and RNA-seq identifies MX1-mediated AP-1 transcriptional regulation as a therapeutic target for Down syndrome

Guo, Z., Zhu, Y., Xiao, H., Dai, R., Yang, W., Xue, W., Zhang, X., Hao, B., & Liao, S. (2023) · Biological Research · doi:10.1186/s40659-023-00474-x · Cited by 15

Transcranial photobiomodulation for neurodevelopmental disorders: a narrative review

Coelho, D. R. A., Renet, C., López-Rodríguez, S., Cassano, P., & Vieira, W. F. (2024) · Photochemical & Photobiological Sciences · doi:10.1007/s43630-024-00613-7 · Cited by 16

A neuropathology case report of a woman with Down syndrome who remained cognitively stable: Implications for resilience to neuropathology

Liou, J., Lou, J. J., Aguilar, L. F., Nakagiri, J., Yong, W. H., Hom, C. L., Doran, E. W., Totoiu, M. O., Lott, I. T., Mapstone, M. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14479 · Cited by 16

Resistance and resilience to Alzheimer's disease in Down syndrome

Boyle, R. T., Koops, E. A., Ances, B. M., Andrews, E. J., Arenaza‐Urquijo, E. M., Bejanin, A., Brickman, A. M., Buckley, R. F., Clas, G. S., Costello, E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70151 · Cited by 14

From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach

Sukreet, S., Rafii, M. S., & Rissman, R. A. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12580 · Cited by 13

γ‐Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer‐Related Pathologies in a Mouse Model of Down Syndrome

Chen, X., Becker, A., Albay, R., Nguyen, P. D., Karachentsev, D., Roberts, A. J., Rynearson, K. D., Tanzi, R. E., & Mobley, W. C. (2024) · Annals of Neurology · doi:10.1002/ana.26958 · Cited by 14

Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome

Zsadanyi, S. E., Morcillo-Nieto, A. O., Aranha, M. R., Aragón, I., Arriola‐Infante, J. E., Vaqué‐Alcázar, L., Montal, V., Pegueroles, J., Arranz, J., Rodríguez‐Baz, Í., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209676 · Cited by 15

Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome

Gorijala, P., Aslam, M. M., Dang, L. T., Xicota, L., Fernandez, M. V., Sung, Y. J., Fan, K., Feingold, E., Surace, E. I., Chhatwal, J. P., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13506 · Cited by 13

TM2D genes regulate Notch signaling and neuronal function in Drosophila

Salazar, J. L., Yang, S.-A., Lin, Y. Q., Li-Kroeger, D., Marcogliese, P. C., Deal, S. L., Neely, G. G., & Yamamoto, S. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009962 · Cited by 13

Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome

Kasri, A., Camporesi, E., Gkanatsiou, E., Boluda, S., Brinkmalm, G., Stimmer, L., Ge, J., Hanrieder, J., Villain, N., Duyckaerts, C. J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02756-4 · Cited by 16

Psychosocial Risk Factors for Alzheimer’s Disease in Patients with Down Syndrome and Their Association with Brain Changes: A Narrative Review

Hamadelseed, O., Elkhidir, I., & Skutella, T. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00361-9 · Cited by 16

ROCK and PDE-5 Inhibitors for the Treatment of Dementia: Literature Review and Meta-Analysis

Lee, D.-H., Lee, J. Y., Hong, D.-Y., Lee, E. C., Park, S.-W., Jo, Y. N., Park, Y. J., Cho, J. Y., Cho, Y. J., Chae, S. H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10061348 · Cited by 13

Weight Loss and Alzheimer’s Disease in Down Syndrome

Fleming, V., Helsel, B. C., Ptomey, L. T., Rosas, H. D., Handen, B. L., Laymon, C. M., Christian, B. T., Head, E., Mapstone, M. E., Lai, F., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220865 · Cited by 12

Untangle the mystery behind DS-associated AD – Is APP the main protagonist?

Elangovan, A., Babu, H. W. S., Iyer, M., Gopalakrishnan, A. V., & Vellingiri, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101930 · Cited by 12

Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a γ‐Secretase Modulator

Chen, X., Sawa, M., Becker, A., Karachentsev, D., Zuo, X., Rynearson, K. D., Tanzi, R. E., & Mobley, W. C. (2023) · Annals of Neurology · doi:10.1002/ana.26659 · Cited by 13

Genetic and chemical disruption of amyloid precursor protein processing impairs zebrafish sleep maintenance

Özcan, G. G., Lim, S., Canning, T., Tirathdas, L., Donnelly, J., Kundu, T., & Rihel, J. (2024) · iScience · doi:10.1016/j.isci.2024.108870 · Cited by 12

The history of Down syndrome–associated Alzheimer's disease; past, present, and future

Maure‐Blesa, L., Carmona‐Iragui, M., Lott, I. T., Head, E., Wısnıewskı, T., Rafii, M. S., Espinosa, J. M., Flórez, J., Mobley, W. C., Holland, A. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70158 · Cited by 12

Proposed diagnostic criteria for mild cognitive impairment in Down syndrome population

Esteba‐Castillo, S., García‐Alba, J., Rodriguez, E., Vaquero, L., Novell, R., Moldenhauer, F., & Castellanos, M. Á. (2021) · Journal of Applied Research in Intellectual Disabilities · doi:10.1111/jar.12959 · Cited by 12

Verteporfin is a substrate-selective γ-secretase inhibitor that binds the amyloid precursor protein transmembrane domain

Castro, M. A., Parson, K. F., Beg, I., Wilkinson, M. C., Nurmakova, K., Levesque, I., Voehler, M., Wolfe, M. S., Ruotolo, B. T., & Sanders, C. R. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101792 · Cited by 13

Probing the proteome to explore potential correlates of increased Alzheimer's‐related cerebrovascular disease in adults with Down syndrome

Moni, F., Petersen, M. E., Zhang, F., Lao, P. J., Zimmerman, M. E., Gu, Y., Gutierrez, J., Rizvi, B. M., Laing, K. K., Igwe, K. C., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12627 · Cited by 12

Altered spontaneous brain activity in Down syndrome and its relation with cognitive outcome

Cañete‐Massé, C., Carbó‐Carreté, M., Peró, M., Cui, S., Yan, C., & Guàrdia‐Olmos, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-19627-1 · Cited by 13

Deciphering the links between psychological stress, depression, and neurocognitive decline in patients with Down syndrome

Poumeaud, F., Mircher, C., Smith, P. J. K., Faye, P.-A., & Sturtz, F. G. (2021) · Neurobiology of Stress · doi:10.1016/j.ynstr.2021.100305 · Cited by 11

Symptoms and age of prodromal Alzheimer’s disease in Down syndrome: a systematic review and meta-analysis

Shimizu, E., Goto‐Hirano, K., Motoi, Y., Arai, M., & Hattori, N. (2024) · Neurological Sciences · doi:10.1007/s10072-023-07292-9 · Cited by 11

DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients

Moreau, M., Carmona‐Iragui, M., Altuna, M., Dalzon, L., Barroeta, I., Vilaire-Meunier, M., Durand, S., Fortea, J., Rebillat, A., & Janel, N. (2022) · Biomedicines · doi:10.3390/biomedicines10061380 · Cited by 12

Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?

Martínez‐Cué, C., & Bartesaghi, R. (2022) · Nutrients · doi:10.3390/nu14142880 · Cited by 10

Physical activity, memory function, and hippocampal volume in adults with Down syndrome

Peven, J. C., Handen, B. L., Laymon, C. M., Fleming, V., Piro‐Gambetti, B., Christian, B., Klunk, W. E., Cohen, A. D., Okonkwo, O. C., & Hartley, S. L. (2022) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2022.919711 · Cited by 12

Investigation of the Neuroprotective Action of Japanese Sake Yeast on Dementia Type of Alzheimer Disease in Rats: Behavioral and Neurobiochemical Assessment

Haghipanah, M., Ghalami, F., Saadat, M., Abbasi-Maleki, S., Salmani, R. H. G., Budde, T., & Moradikor, N. (2023) · NeuroSci · doi:10.3390/neurosci4010006 · Cited by 11

The Global Deterioration Scale for Down Syndrome Population (GDS-DS): A Rating Scale to Assess the Progression of Alzheimer’s Disease

Rodriguez, E., García‐Alba, J., Novell, R., & Esteba‐Castillo, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20065096 · Cited by 11

Plasma NT1‐tau and Aβ42 correlate with age and cognitive function in two large Down syndrome cohorts

Stern, A. M., Pelt, K. L. V., Liu, L., Anderson, A. K., Ostaszewski, B. L., Mapstone, M. E., O’Bryant, S. E., Petersen, M. E., Christian, B. T., Handen, B. L., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13382 · Cited by 11

TTC3-Mediated Protein Quality Control, A Potential Mechanism for Cognitive Impairment

Zhou, X., Chen, X., Hong, T., Zhang, M., Cai, Y., & Cui, L. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01060-z · Cited by 10

The Brain Health Diplomat's Toolkit: supporting brain health diplomacy leaders in Latin America and the Caribbean

Dawson, W. D., Booi, L., Pintado‐Caipa, M., de Oliveira, M. O., Kornhuber, A., Spoden, N., Golonka, O., Shallcross, L., Davidziuk, A., Cominetti, M. R., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100627 · Cited by 10

Enhancing protein O-GlcNAcylation in down syndrome mice mitigates memory dysfunctions through the rescue of mitochondrial bioenergetics, stress responses and pathological markers

Lanzillotta, C., Prestia, F., Greco, V., Iavarone, F., Cordella, F., Sette, C., Forte, E., Tramutola, A., Lanzillotta, S., Cassano, T., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103769 · Cited by 10

Complexity Analysis of the Default Mode Network Using Resting-State fMRI in Down Syndrome: Relationships Highlighted by a Neuropsychological Assessment

Figueroa-Jiménez, M. D., Carbó‐Carreté, M., Cañete‐Massé, C., Zarabozo‐Hurtado, D., Peró, M., Estrada, J. G. S., & Guàrdia‐Olmos, J. (2021) · Brain Sciences · doi:10.3390/brainsci11030311 · Cited by 12

Composite Scores of Plasma Tau and β-Amyloids Correlate with Dementia in Down Syndrome

Fang, W.-Q., Hwu, W., Chien, Y., Yang, S., Chieh, J.-J., Chang, L.-M., Huang, A.-C., Lee, N., & Chiu, M. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00585 · Cited by 10

GIRK2 Channels in Down Syndrome and Alzheimer’s Disease

Kleschevnikov, A. M. (2022) · Current Alzheimer Research · doi:10.2174/1567205020666221223122110 · Cited by 10

Type I Interferon Signaling Drives Microglial Dysfunction and Senescence in Human iPSC Models of Down Syndrome and Alzheimer's DiseasePreprint

Jin, M., Xu, R., Alam, M. M., Ma, Z., Zhu, S., Wang, L., Martini, A. C., Bernabucci, M., Xie, P., Kwan, K. Y., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3985173 · Cited by 10

Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndromePreprint

Edwards, N. C., Lao, P. J., Alshikho, M. J., Ericsson, O. M., Rizvi, B. M., Petersen, M. E., O’Bryant, S. E., Aguilar, L. F., Simoes, S., Mapstone, M. E., et al. (2023) · medRxiv · doi:10.1101/2023.11.28.23298693 · Cited by 10

Lipid Profile, Eating Habit, and Physical Activity in Children with Down Syndrome: A Prospective Study

Pecoraro, L., Zadra, M., Cavallin, F., Lauriola, S., PIACENTINI, G. L., & Pietrobelli, A. (2024) · Diseases · doi:10.3390/diseases12040068 · Cited by 11

Brain insulin resistance in Down syndrome: Involvement of PI3K-Akt/mTOR axis in early-onset of Alzheimer's disease and its potential as a therapeutic target

Azimzadeh, M., Cheah, P.-S., & Ling, K. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150713 · Cited by 15

Blood‐based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta‐analysis

Zhou, Y., Sheehan, R., Guo, L., & Strydom, A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70135 · Cited by 10

Hyperactivation of RAB5 disrupts the endosomal Rab cascade leading to endolysosomal dysregulation in Down syndrome: A necessary role for increased APP gene dose

Chen, X., Zuo, X., Becker, A., & Mobley, W. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70046 · Cited by 9

Antisense oligonucleotides directed against App and Rab5 normalized endosomal Rab activity and reversed DS‐AD‐linked degenerative phenotypes in the Dp16 mouse model of Down syndrome

Chen, X., Zuo, X., Becker, A., Mante, M., Florio, J. B., Jadhav, S. G., Albay, R., Johnstone, A. D., Karachentsev, D., Rissman, R. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70022 · Cited by 9

Serotonin-mediated regulation of mitophagy in Alzheimer's disease: Mechanistic insights and therapeutic potential

Sultana, O. F., Bandaru, M., Bushra, M. A., Reddy, P. H., & Reddy, A. P. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102957 · Cited by 11

Biomarkers in Down syndrome can help us understand Alzheimer's disease

Head, E., & Ances, B. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30916-8 · Cited by 9

Development of a symptom menu to facilitate Goal Attainment Scaling in adults with Down syndrome-associated Alzheimer’s disease: a qualitative study to identify meaningful symptoms

Knox, K., Stanley, J., Hendrix, J. A., Hillerstrom, H., Dunn, T., Achenbach, J., Chicoine, B. A., Lai, F., Lott, I. T., Stanojevic, S., et al. (2021) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00278-7 · Cited by 9

Views on the impact of the COVID ‐19 pandemic on health in people with Down syndrome from diverse backgrounds

Santoro, S. L., Baker, S., Blake, J. M., Cabrera, M. J., Caughman, K., Chung, J. A., Cullen, S., Gallagher, M., Haugen, K. L., Hoke‐Chandler, R., et al. (2023) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.63233 · Cited by 9

Definition, assessment and management of frailty for people with intellectual disabilities: A scoping review

Grohmann, D., Wellsted, D. M., & Mengoni, S. E. (2024) · Journal of Applied Research in Intellectual Disabilities · doi:10.1111/jar.13219 · Cited by 8

Impaired glymphatic clearance is an important cause of Alzheimer’s disease

Hazzard, I., Batiste, M., Luo, T., Cheung, C., & Lui, F. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00091 · Cited by 9

Single‐nucleus analysis reveals oxidative stress in Down syndrome basal forebrain neurons at birth

West, N. R., Arachchilage, K. H., Knaack, S., MacGregor, S., Hosseini, M., Risgaard, R. D., Kumarage, P., Martinez, J. L., Zhang, S., Wang, D., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70445 · Cited by 8

Molecular cartography of the human down syndrome and trisomic mouse brain

Feng, M. Y., Cao, W., Tahmasian, N., Kukreja, B., Li, G. L., Rusu, B., Youn, J., & Kalish, B. T. (2025) · Nature Communications · doi:10.1038/s41467-025-63752-0 · Cited by 9

Plasma p-tau217 as a biomarker of Alzheimer’s disease pathology in individuals with Down syndrome

Huber, H., Arranz, J., Arslan, B., Leuzy, A., Kittel, O., Molfetta, G. D., Benejam, B., Videla, L., Barroeta, I., Soriano, L. D. H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65882-x · Cited by 17

Dementia in People with Severe/Profound Intellectual (and Multiple) Disabilities: Practice-Based Observations of Symptoms

Wissing, M. B. G., Fokkens, A., Dijkstra, R., Hobbelen, H. J. S. M., van der Putten, A. A. J., Deyn, P. P. D., Waninge, A., & Dekker, A. D. (2022) · Journal of Mental Health Research in Intellectual Disabilities · doi:10.1080/19315864.2022.2061092 · Cited by 10

Toward the Identification of Neurophysiological Biomarkers for Alzheimer’s Disease in Down Syndrome: A Potential Role for Cross-Frequency Phase-Amplitude Coupling Analysis

Victorino, D. B., Faber, J., Pinheiro, D. J. L. L., Scorza, F. A., de Almeida, A.-C. G., Costa, A. C. S., & Scorza, C. A. (2022) · Aging and Disease · doi:10.14336/ad.2022.0906 · Cited by 8

Perspectives on pain in Down syndrome

Shaikh, A., Li, Y., & Lu, J. (2023) · Medicinal Research Reviews · doi:10.1002/med.21954 · Cited by 10

The association between cardiovascular health and cognition in adults with Down syndrome

Frank, L., Helsel, B. C., Dodd, D., Bodde, A. E., Danon, J. C., Sherman, J. R., Forsha, D. E., Szabo‐Reed, A. N., Washburn, R. A., Donnelly, J. E., et al. (2023) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-023-09510-z · Cited by 10

TransPhoM-DS Study Grant Report: Rationale and Protocol for Investigating the Efficacy of Low-Power Transcranial Photobiomodulation on Language, Executive Function, Attention, and Memory in Down Syndrome

Vieira, W. F., Coelho, D. R. A., Gersten, M. B., Puerto, A. M. H., Kalli, S., González-Garibay, G., McEachern, K. M., Clancy, J. A., Skotko, B. G., Abbeduto, L., et al. (2024) · Photonics · doi:10.3390/photonics11070670 · Cited by 9

Antiviral Immune Response in Alzheimer’s Disease: Connecting the Dots

Roy, E. R., & Cao, W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.577744 · Cited by 8

Cell type characterization of spatiotemporal gene co-expression modules in Down syndrome brain

Seol, S., Kwon, J., & Kang, H. J. (2022) · iScience · doi:10.1016/j.isci.2022.105884 · Cited by 8

Genetics of Alzheimer's disease in adults with Down syndrome

Lee, J. H., Dang, L. T., Pang, D. I., Krinsky‐McHale, S. J., & Schupf, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00001-3 · Cited by 1

Novel insights into Alzheimer's disease through the study of individuals with Down syndrome

Head, E., Cohen, A. D., Fortea, J., & McGlinchey, E. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71074 · Cited by 1

Alzheimer's disease in Down syndrome

Fortea, J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz70856_096000

Brain Aging and Alzheimer’s Disease in Down Syndrome

Helman, A. M., Pelt, K. L. V., Schmitt, F. A., & Head, E. (2022) · doi:10.1093/oxfordhb/9780190645441.013.22 · Cited by 1

Alzheimer's Disease in Down's Syndrome: A Review

Karlinsky, H. (1986) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1986.tb04304.x · Cited by 31